Lenalidomide Sandoz (Lenalidomide)

• Lenalidomide Sandoz is an immunomodulatory drug used in hematologic malignancies and related disorders.
• Multiple myeloma: incorporated into combination regimens to reduce disease burden and prolong survival.
• Myelodysplastic syndromes with del(5q): administered to improve blood counts and decrease transfusion dependence.
• Mantle cell lymphoma: used as part of therapy to achieve disease control in eligible patients.

• Lenalidomide binds to the cereblon component of the CRL4CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory, and direct anti‑tumor activities that suppress malignant plasma cells and related neoplastic cells.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: feeling of persistent tiredness.
• Diarrhea: loose stools occurring intermittently.
• Nausea: sensation of queasiness often accompanied by vomiting.
• Rash: mild skin eruptions or itching.
• Low blood counts: mild neutropenia or anemia.
• Peripheral edema: swelling of the extremities.

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism: clot formation in veins.
• Severe neutropenia: markedly reduced white blood cells increasing infection risk.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Secondary primary malignancies: emergence of new cancers.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatotoxicity: significant liver enzyme elevation or liver injury.

• Before initiating therapy, clinicians should evaluate baseline laboratory values and assess patient risk factors.
• Pregnancy testing: confirm negative status before starting and use effective contraception throughout treatment and for at least 4 weeks after discontinuation.
• Thromboembolic risk: consider prophylactic anticoagulation in patients with additional risk factors.
• Renal function: adjust monitoring in patients with impaired kidney function.
• Infection monitoring: watch for signs of infection due to possible neutropenia.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lenalidomide may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce lenalidomide exposure.
• Anticoagulants (e.g., warfarin): increased risk of bleeding.
• Immunosuppressants: heightened infection risk.

Moderate Interactions (Monitor Closely)

• P-glycoprotein inhibitors: potential increase in plasma levels.
• Other myelosuppressive agents: additive bone‑marrow suppression.
• Vaccines (live attenuated): reduced vaccine efficacy or increased adverse events.